Skip to main content

Table 3 Correlation of BRAF IHC results and clinicopathological characteristics

From: Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

 

BRAF IHC

 

Characteristics

NEGATIVE (N = 29)

POSITIVE (N = 34)

p value

Sex

 Male

20 (68.97)

15 (44.12)

0.0479*

 Female

9 (31.03)

19 (55.88)

 

Age

 

64.55 ± 12.94

51.18 ± 15.33

0.001*

Stage at diagnosis

 I + II

7 (24.14)

12 (36.36)

0.2975

 III + IV

22 (75.86)

21 (63.64)

 

Metastatic stage

 M1a

8 (27.59)

5 (14.71)

0.0564

 M1b

1 (3.45)

8 (23.53)

 

 M1c

20 (68.97)

21 (61.76)

 

Brain metastasis

 No

20 (68.97)

21 (61.76)

0.5501

 Yes

9 (31.03)

13 (38.24)

 

N° metastasis

  ≤ 2

13 (44.83)

15 (44.12)

0.9549

  > 2

16 (55.17)

19 (55.88)

 
  1. *p < 0.005